Fifty-nine biotechs raised more than $3.8 billion in IPOs in 2013, with 16 companies raising about $945 million in the last quarter of the year. The companies in the IPO class of 2013 were up a median of 39% from their initial valuations, led by cancer vaccine company Immunicum AB (SSE:IMMU) and Japanese peptide discovery company PeptiDream Inc. (Tokyo:4587). Both companies' market caps are up more than 4x from